Utility wants to turn 40 year old antibiotic into US sucess
Since the purchase of an old Leo Pharma antibiotic, Danish-founded Utility Therapeutics has rushed through the regulatory process in the US, where the company aims to introduce the drug. Now, the search for funding for the clinical programs has begun.
It has been less than a year since Mark Beards took position as CEO in Utility Therapeutics. However, things have moved fast since he joined the company.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
